ABK Biomedical

Founders: Dr. Daniel Boyd, Dr. Bob Abraham and Dr. Sharon Kehoe

Developers of OccluRad particles, which are used to treat fibroid tumours in women.

OccluRad is designed to treat a rather common medical condition: approx. 40 per cent of women over the age of 35 worldwide develop benign tumours in their uterus and many of them require a hysterectomy. To try and prevent this, clinicians have begun injecting tiny particles through the skin that impede blood flow to the tumour so it gradually reduces in size.

One problem with this, though, is that the particles can’t be seen in an X-ray, meaning that in order to see if the particles are working, physicians have to use a potentially toxic dye so they show up in the scans. In contrast, OccluRad particles are completely visible during X-rays, eliminating the need for toxic dyes.

Contact:
Dr. Daniel Boyd
d.boyd@dal.ca(902) 494-6347
Dentistry Building, Room 5195
5981 University Avenue
Halifax, NS
B3H 1W2